5 Healthcare Stocks Under $10 Ready To Pop

Synergy Pharmaceuticals Inc (NASDAQ:SGYP) ranks third with a staggering increase in hedge fund backing for the company during the second quarter, as 31 funds had $180.43 million worth of investments in the company compared to 11 firms with $31.89 million in shares at the end of March. In July, Synergy announced that its lead experimental drug, plecantide, which treats constipation with no known causes, met its primary endpoint in a second late-stage study. Peak sales of the drug are expected to exceed $800 million by 2023. Synergy Pharmaceuticals Inc (NASDAQ:SGYP) is going to file a New Drug Application for the treatment with the FDA in the first quarter of 2016. Meanwhile, the company’s stock price has surged by nearly 150% so far this year. John Paulson‘s Paulson & Co is the largest shareholder of Synergy Pharmaceuticals Inc (NASDAQ:SGYP) within our database, owning some 5.78 million shares valued at $47.99 million.